Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Public ClinicalTrials.gov record NCT05565417. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Study identification
- NCT ID
- NCT05565417
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Immunitas Therapeutics
- Industry
- Enrollment
- 67 participants
Conditions and interventions
Conditions
- Burkitt Lymphoma
- Colorectal Cancer
- Cutaneous Squamous Cell Carcinoma
- Diffuse Large B Cell Lymphoma
- Esophageal Cancer
- Follicular Lymphoma
- Head and Neck Squamous Cell Carcinoma
- Hodgkin Lymphoma
- Hormone Receptor Positive Breast Carcinoma
- Non Small Cell Lung Cancer
- Small Bowel Cancer
- Triple Negative Breast Cancer
Interventions
- Fruquintinib Combination Product
- IMT-009 Drug
Combination Product · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 27, 2022
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2025
- Last update posted
- Oct 15, 2025
2022 – 2026
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 9618 | Tucson | Arizona | 85711 | — |
| Site 5000 | Denver | Colorado | 80218 | — |
| Site 4100 | Orlando | Florida | 32827 | — |
| Site 4060 | Sarasota | Florida | 34232 | — |
| Site 4500 | Oklahoma City | Oklahoma | 73104 | — |
| Site 9280 | Portland | Oregon | 97239 | — |
| Site 3000 | Nashville | Tennessee | 37203 | — |
| Site 9384 | Austin | Texas | 78705 | — |
| Site 9112 | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05565417, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2025 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05565417 live on ClinicalTrials.gov.